Rabbit Polyclonal CYLD antibody. Suitable for WB, ICC/IF and reacts with Human samples. Cited in 4 publications. Immunogen corresponding to Recombinant Fragment Protein within Human CYLD aa 1-250.
pH: 7
Preservative: 0.025% Proclin 300
Constituents: 79% PBS, 20% Glycerol (glycerin, glycerine)
WB | ICC/IF | |
---|---|---|
Human | Tested | Tested |
Mouse | Predicted | Predicted |
Rat | Predicted | Predicted |
Cow | Predicted | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/500.00000 - 1/3000.00000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Cow | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100.00000 - 1/1000.00000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Cow | Dilution info - | Notes - |
Select an associated product type
Deubiquitinase that specifically cleaves 'Lys-63'- and linear 'Met-1'-linked polyubiquitin chains and is involved in NF-kappa-B activation and TNF-alpha-induced necroptosis (PubMed:18313383, PubMed:18636086, PubMed:26670046, PubMed:26997266, PubMed:27458237, PubMed:27591049, PubMed:29291351, PubMed:32185393). Negatively regulates NF-kappa-B activation by deubiquitinating upstream signaling factors (PubMed:12917689, PubMed:12917691, PubMed:32185393). Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation (PubMed:12917690). Negative regulator of Wnt signaling (PubMed:20227366). Inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilization of microtubules (PubMed:19893491). Plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarization, cell migration, and angiogenesis (PubMed:18222923, PubMed:20194890). Required for normal cell cycle progress and normal cytokinesis (PubMed:17495026, PubMed:19893491). Inhibits nuclear translocation of NF-kappa-B (PubMed:18636086). Plays a role in the regulation of inflammation and the innate immune response, via its effects on NF-kappa-B activation (PubMed:18636086). Dispensable for the maturation of intrathymic natural killer cells, but required for the continued survival of immature natural killer cells (By similarity). Negatively regulates TNFRSF11A signaling and osteoclastogenesis (By similarity). Involved in the regulation of ciliogenesis, allowing ciliary basal bodies to migrate and dock to the plasma membrane; this process does not depend on NF-kappa-B activation (By similarity). Ability to remove linear ('Met-1'-linked) polyubiquitin chains regulates innate immunity and TNF-alpha-induced necroptosis: recruited to the LUBAC complex via interaction with SPATA2 and restricts linear polyubiquitin formation on target proteins (PubMed:26670046, PubMed:26997266, PubMed:27458237, PubMed:27591049). Regulates innate immunity by restricting linear polyubiquitin formation on RIPK2 in response to NOD2 stimulation (PubMed:26997266). Involved in TNF-alpha-induced necroptosis by removing linear ('Met-1'-linked) polyubiquitin chains from RIPK1, thereby regulating the kinase activity of RIPK1 (By similarity). Negatively regulates intestinal inflammation by removing 'Lys-63' linked polyubiquitin chain of NLRP6, thereby reducing the interaction between NLRP6 and PYCARD/ASC and formation of the NLRP6 inflammasome (By similarity). Removes 'Lys-63' linked polyubiquitin chain of MAP3K7, which inhibits phosphorylation and blocks downstream activation of the JNK-p38 kinase cascades (PubMed:29291351). Removes also 'Lys-63'-linked polyubiquitin chains of MAP3K1 and MA3P3K3, which inhibit their interaction with MAP2K1 and MAP2K2 (PubMed:34497368).
CYLD1, KIAA0849, HSPC057, CYLD, Ubiquitin carboxyl-terminal hydrolase CYLD, Deubiquitinating enzyme CYLD, Ubiquitin thioesterase CYLD, Ubiquitin-specific-processing protease CYLD
Rabbit Polyclonal CYLD antibody. Suitable for WB, ICC/IF and reacts with Human samples. Cited in 4 publications. Immunogen corresponding to Recombinant Fragment Protein within Human CYLD aa 1-250.
pH: 7
Preservative: 0.025% Proclin 300
Constituents: 79% PBS, 20% Glycerol (glycerin, glycerine)
CYLD also known as cylindromatosis or turban tumor syndrome is a protein that serves mainly as a deubiquitinating enzyme. This protein has a mass of approximately 108 kDa and is expressed in a variety of tissues most notably the skin and lungs. It is a negative regulator of cell signaling cascades particularly in pathways where ubiquitination needs to be controlled. CYLD interacts directly with other proteins to remove ubiquitin chains a process that is essential for regulating the degradation of proteins and maintaining cellular functions.
The deubiquitination activity of CYLD plays a critical role in controlling inflammation and cell proliferation. This protein often associates with complexes that regulate the activity of NF-kB signaling pathways. By removing ubiquitin from specific substrates CYLD limits the activation of NF-kB therefore modulating inflammatory responses in the body. Additionally CYLD's role extends to controlling cell cycle progression and preventing uncontrolled cell growth making it essential in tissue homeostasis.
CYLD is a significant regulator of the NF-kB and Wnt signaling pathways. It interacts with proteins such as TRAF2 TRAF6 and NEMO which are important in these pathways. CYLD prevents constitutive activation of NF-kB therefore serving as a checkpoint in inflammation and immune response. In the Wnt signaling pathway CYLD's regulation affects the turnover of beta-catenin highlighting its role in developmental processes and cellular differentiation.
CYLD is closely associated with cylindromatosis and familial adenomatous polyposis. Mutations or disruptions in CYLD function can lead to these conditions where abnormal cell proliferation occurs due to unregulated NF-kB activation. In cylindromatosis CYLD mutations result in the benign skin tumors known as cylindromas. Furthermore its connection to proteins like TRAF2 links it to other tumorigenic processes emphasizing CYLD's influence in both inflammatory and proliferative disorders.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Immunofluorescent analysis of methanol-fixed HeLa cells labeling CYLD with ab153698 at 1/200 dilution. (Lower image shows cells co-stained with Hoechst 33342.
7.5% SDS PAGE
All lanes: Western blot - Anti-CYLD antibody - N-terminal (ab153698) at 1/1000 dilution
All lanes: HeLa whole cell lysate at 30 µg
Predicted band size: 107 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com